Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8,165,808
-
Total 13F shares
-
85,366,944
-
Share change
-
-1,738,021
-
Total reported value
-
$126,342,685
-
Put/Call ratio
-
5.6%
-
Price per share
-
$1.48
-
Number of holders
-
106
-
Value change
-
-$2,697,551
-
Number of buys
-
50
-
Number of sells
-
52
Institutional Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q3 2023
As of 30 Sep 2023,
Atara Biotherapeutics, Inc. - Common Stock (ATRA) was held by
106 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
85,366,944 shares.
The largest 10 holders included
BAUPOST GROUP LLC/MA, JPMORGAN CHASE & CO, WASATCH ADVISORS LP, BlackRock Inc., VANGUARD GROUP INC, MAVERICK CAPITAL LTD, Redmile Group, LLC, GOLDMAN SACHS GROUP INC, D. E. Shaw & Co., Inc., and STATE STREET CORP.
This page lists
107
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.